U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Endometrial Clear Cell Adenocarcinoma

MedGen UID:
1683130
•Concept ID:
C4764208
•
Neoplastic Process

Definition

Endometrial clear cell adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Endometrial Clear Cell Adenocarcinoma

Professional guidelines

PubMed

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E
Oncology 2007;73(3-4):177-84. Epub 2008 Apr 16 doi: 10.1159/000127384. PMID: 18418010
Recurrent stage I endometrial carcinoma: results of treatment and prognostic factors.
Mandell LR, Nori D, Hilaris B
Int J Radiat Oncol Biol Phys 1985 Jun;11(6):1103-9. doi: 10.1016/0360-3016(85)90056-2. PMID: 3997592

Recent clinical studies

Etiology

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM
Cancer Immunol Immunother 2011 Jul;60(7):975-84. Epub 2011 Apr 2 doi: 10.1007/s00262-011-1010-x. PMID: 21461842Free PMC Article
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774

Diagnosis

Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH
Int J Gynecol Cancer 2015 Jul;25(6):1015-22. doi: 10.1097/IGC.0000000000000453. PMID: 26098089Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151

Therapy

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
Dogan NU, Dogan S, Erol M, Uzun BT
Gynecol Oncol 2020 Feb;156(2):511. Epub 2019 Dec 29 doi: 10.1016/j.ygyno.2019.12.004. PMID: 31892416
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM
Cancer Immunol Immunother 2011 Jul;60(7):975-84. Epub 2011 Apr 2 doi: 10.1007/s00262-011-1010-x. PMID: 21461842Free PMC Article

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM
Cancer Immunol Immunother 2011 Jul;60(7):975-84. Epub 2011 Apr 2 doi: 10.1007/s00262-011-1010-x. PMID: 21461842Free PMC Article
Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Int J Gynecol Cancer 2009 Jul;19(5):860-6. doi: 10.1111/IGC.0b013e3181a8331f. PMID: 19574774

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E
Oncology 2007;73(3-4):177-84. Epub 2008 Apr 16 doi: 10.1159/000127384. PMID: 18418010

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...